Sutacimig

About Hemab Therapeutics

Hemab Therapeutics is a private, clinical-stage biotech focused on addressing the significant unmet need in rare bleeding disorders like Glanzmann Thrombasthenia (GT) and Von Willebrand Disease (VWD). The company has advanced two lead clinical assets, sutacimig (in Phase 2/3 for GT) and HMB-002 (in Phase 1/2 for VWD), with promising data and regulatory support including a Breakthrough Therapy Designation for sutacimig. Backed by a substantial $157 million Series C financing, Hemab is well-positioned to advance its pipeline toward pivotal studies and expand its research into other underserved hemostatic disorders.

Therapeutic Areas